LASIX (furosemide) by Bausch Health is clinical pharmacology investigations into the mode of action of lasix have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. First approved in 1966.
Drug data last refreshed 17h ago · AI intelligence enriched 20h ago
LASIX (furosemide) is a loop diuretic approved in 1966 that inhibits sodium and chloride reabsorption in the loop of Henle and distal tubule, producing rapid onset diuresis within 1 hour. It is used primarily for edema associated with congestive heart failure, liver cirrhosis, and renal disease, as well as hypertension management. The drug's high efficacy derives from its unique site of action independent of carbonic anhydrase or aldosterone inhibition.
Long-established generic product with minimal Part D volume and declining proprietary margins; brand team likely focused on cost management and market stabilization rather than expansion.
CLINICAL PHARMACOLOGY Investigations into the mode of action of LASIX have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that LASIX inhibits primarily the absorption of sodium and…
Worked on LASIX at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Loop Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLASIX offers minimal career growth potential as a mature, fully genericized product with no active clinical pipeline or brand expansion opportunities. Roles on this product are primarily focused on compliance, cost management, and defending market share against generic competitors rather than driving innovation or career advancement.